Eiger Biopharmaceuticals Inc. (NASDAQ:EIGR) – Research analysts at Oppenheimer issued their FY2018 earnings per share estimates for Eiger Biopharmaceuticals in a note issued to investors on Monday, March 12th, Zacks Investment Research reports. Oppenheimer analyst J. Olson forecasts that the biotechnology company will post earnings of ($3.88) per share for the year. Oppenheimer currently has a “Buy” rating on the stock. Oppenheimer also issued estimates for Eiger Biopharmaceuticals’ FY2019 earnings at ($4.01) EPS and FY2020 earnings at ($4.44) EPS.
Eiger Biopharmaceuticals (NASDAQ:EIGR) last announced its earnings results on Monday, March 12th. The biotechnology company reported ($1.11) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.02) by ($0.09).
A number of other equities analysts have also recently commented on the company. Ladenburg Thalmann initiated coverage on Eiger Biopharmaceuticals in a report on Wednesday, January 3rd. They issued a “buy” rating and a $32.00 target price on the stock. Zacks Investment Research raised Eiger Biopharmaceuticals from a “hold” rating to a “buy” rating and set a $15.00 target price on the stock in a report on Tuesday, January 9th. Piper Jaffray reaffirmed an “overweight” rating and issued a $17.00 target price (down from $35.00) on shares of Eiger Biopharmaceuticals in a report on Tuesday, January 16th. ValuEngine cut Eiger Biopharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Thursday, March 1st. Finally, Wedbush decreased their price target on Eiger Biopharmaceuticals from $36.00 to $34.00 and set an “outperform” rating on the stock in a report on Thursday, March 22nd. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $27.25.
Eiger Biopharmaceuticals stock traded down $1.20 during trading on Thursday, reaching $9.10. The company had a trading volume of 64,458 shares, compared to its average volume of 68,335. Eiger Biopharmaceuticals has a 52 week low of $6.10 and a 52 week high of $16.20. The stock has a market cap of $108.42, a P/E ratio of -1.87 and a beta of 1.58. The company has a debt-to-equity ratio of 0.58, a quick ratio of 5.85 and a current ratio of 5.85.
In other Eiger Biopharmaceuticals news, insider Joanne Quan sold 4,000 shares of the firm’s stock in a transaction dated Monday, April 2nd. The stock was sold at an average price of $10.00, for a total transaction of $40,000.00. Following the sale, the insider now directly owns 4,000 shares of the company’s stock, valued at $40,000. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 28.80% of the stock is owned by company insiders.
A number of large investors have recently bought and sold shares of the business. Prosight Management LP bought a new stake in Eiger Biopharmaceuticals during the fourth quarter valued at about $9,469,000. Jennison Associates LLC bought a new stake in Eiger Biopharmaceuticals during the fourth quarter valued at about $8,430,000. Sphera Funds Management LTD. raised its holdings in Eiger Biopharmaceuticals by 35.0% during the third quarter. Sphera Funds Management LTD. now owns 520,269 shares of the biotechnology company’s stock valued at $5,723,000 after acquiring an additional 134,968 shares during the period. Armistice Capital LLC bought a new stake in Eiger Biopharmaceuticals during the fourth quarter valued at about $5,357,000. Finally, Stonepine Capital Management LLC bought a new stake in Eiger Biopharmaceuticals during the fourth quarter valued at about $2,093,000. 68.96% of the stock is currently owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: “Eiger Biopharmaceuticals Inc. Expected to Post FY2018 Earnings of ($3.88) Per Share (EIGR)” was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another domain, it was stolen and republished in violation of U.S. and international copyright laws. The original version of this news story can be accessed at https://www.dispatchtribunal.com/2018/04/07/brokers-set-expectations-for-eiger-biopharmaceuticals-incs-fy2018-earnings-eigr.html.
Eiger Biopharmaceuticals Company Profile
Eiger BioPharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on providing various products for the treatment of orphan diseases in the United States. Its product candidate pipeline includes Lonafarnib for the treatment of hepatitis delta virus (HDV) infection; PEG-interferon Lambda-1a (Lambda) for HDV infection; Exendin 9-39 for post-bariatric hypoglycemia; and Ubenimex for the treatment of pulmonary arterial hypertension and lymphedema, which are under Phase II clinical trials.
Get a free copy of the Zacks research report on Eiger Biopharmaceuticals (EIGR)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Eiger Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.